Akari Therapeutics, Plc — Operating Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/f50d1c08-b1a7-4528-90ea-668eeecfda5a/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-17.3M | 2025-01-01 – 2025-12-31 | evidence 0001493152-26-013664 |
| FY 2024 | $-21.6M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-054278 |
| FY 2023 | $-13.1M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-104428 |
| FY 2022 | $-11.8M | 2022-01-01 – 2022-12-31 | evidence 0000950170-24-104428 |
| FY 2021 | $-17.2M | 2021-01-01 – 2021-12-31 | evidence 0001410578-22-001546 |
| FY 2020 | $-18.0M | 2020-01-01 – 2020-12-31 | evidence 0001104659-21-052672 |
| FY 2019 | $-17.0M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-040722 |
| FY 2018 | $-20.8M | 2018-01-01 – 2018-12-31 | evidence 0001104659-21-052672 |
| FY 2017 | $-37.8M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-038891 |
| FY 2016 | $-27.2M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-018167 |
| FY 2015 | $-30.6M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-089697 |
| FY 2014 | $-1.9M | 2014-01-01 – 2014-12-31 | evidence 0001144204-16-089697 |
| FY 2013 | $-3.6M | 2013-01-01 – 2013-12-31 | evidence 0001144204-14-017308 |
| FY 2012 | $-13.7M | 2004-10-07 – 2012-12-31 | evidence 0001144204-13-022773 |
| FY 2011 | $-2.2M | 2011-01-01 – 2011-12-31 | evidence 0001144204-13-022773 |
| FY 2010 | $-792.0k | 2010-01-01 – 2010-12-31 | evidence 0001144204-13-022773 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).